Observed Signal · Sep 23, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 3/5 · Sentiment: Positive

Anthropic and Nvidia back Basecamp Research in $140M Series C

Executive Signal Summary

London-based life sciences startup Basecamp Research has raised $140 million in a Series C funding round led by venture firm S32. Nvidia's venture arm NVentures and Anthropic's Anthology Fund participated, alongside other new and returning investors. The company uses AI and biodiversity data to design new medicines, with a focus on in vivo cell therapy. The funds will be used to train next-generation AI models and advance its pipeline of AI-designed therapeutics. Basecamp has raised $225 million in total.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

Funding round for a life sciences AI startup with participation from major tech investors, but not directly related to AdTech or marketing technology.

SIGNAL RADAR

Track NVIDIA Signals & Market Shifts in Real-Time

Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.

Start Monitoring
Verified primary sourcesAutomated briefingsInstant watchlist setup

Key Takeaways & Evidence Grounding

  • Basecamp Research raised $140 million in a Series C round.
  • The round was led by S32, with participation from Nvidia's NVentures and Anthropic's Anthology Fund.
  • Other new investors include Catalio, NATO Innovation Fund, Rockefeller, European Tech Collective, and UK Sovereign AI Fund.
  • The company will use the funding to train new AI models and advance its therapeutic pipeline.
  • Basecamp has raised a total of $225 million to date.

Ontology Mapping & Concepts

Large Language Models (LLM) & AIPrivate Equity, VC & Investor#in vivo cell therapy#biological foundation AI models
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: Tech.eu (European Tech & Deals)•Published: Sep 23, 2026

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

AI in Drug DevelopmentOct 27, 2026

Atlas Bio Raises $12.5M for AI Clinical Trial Simulations

Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.

Read assessment
AISep 22, 2026

Biolevate raises €30M Series A for life sciences AI

Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.

Read assessment
FinancialsNov 4, 2026

bit.bio Raises $25M Series D for Cell Models

bit.bio, a human cell programming company, announced it has closed a $25 million Series D funding round. The investment will be used to expand its portfolio of human cell models and increase access to its technology for pharmaceutical, biotechnology, and research organizations. The round includes participation from existing investor M&G Investments and Dr Jonathan Milner, founder and former CEO of Abcam. The company's opti-ox™ platform enables the production of defined human cell types at scale, and its ioCells portfolio includes over 50 cell types for drug discovery and disease research. The funding comes as AI accelerates drug candidate identification and there is growing demand for alternatives to animal testing.

Read assessment
Executive Briefing & Watchlist

Receive all future signals for NVIDIA & competitors in your briefing

Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.

Daily primary source scansCurated executive briefingsUnsubscribe anytime